Leveraging DNA-based biomaterials for advanced cancer immunotherapy

Area of Science:

• Biomaterials Science
• Immunology
• Nanotechnology

Background:

• DNA-based biomaterials are emerging as versatile platforms in cancer immunotherapy.
• Their programmability, structural precision, and biocompatibility enable rational design at the molecular level.

Purpose of the Study:

• To summarize design principles and applications of DNA biomaterials in cancer immunotherapy.
• To highlight how DNA architectures can engineer immune cell signaling and fate for next-generation therapies.
• To discuss translational challenges and future perspectives for clinical implementation.

Main Methods:

• Review of literature on DNA-based biomaterials (tetrahedra, origami, nanorobots, hydrogels, hybrid nanoparticles).
• Synthesis of design principles and applications in immune regulation, vaccine development, and combination therapy.
• Analysis of how DNA architecture influences immune cell signaling and fate.

Main Results:

• DNA biomaterials facilitate targeted delivery, immune modulation, and controlled therapeutic agent activation.
• These materials enhance antigen presentation, regulate immune microenvironments, and alleviate tumor-induced immunosuppression.
• Programmable spatial organization of DNA architectures can directly engineer immune cell signaling and fate.

Conclusions:

• DNA-based biomaterials hold significant promise for advancing cancer immunotherapy.
• Harnessing DNA architecture's properties is crucial for developing next-generation immunotherapies.
• Addressing translational challenges is essential for clinical implementation of these intelligent biomaterials.